Andere Sprachen TRACON Pharmaceuticals, Inc.

Aktien

A3EVGP

US89237H3084

TCON

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 06.05.2024			% 5 Tage	% 1. Jan.
1,81 ^USD	-2,69 %		-3,45 %	-48,32 %

03.04.	TRACON Pharmaceuticals gibt ein Update zur laufenden Phase 2-Zulassungsstudie ENVASARC nach der Empfehlung des unabhängigen Datenüberwachungskomitees, die Studie wie geplant fortzusetzen	CI
06.03.	TRACON PHARMACEUTICALS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

TRACON Pharmaceuticals Announces Reverse Stock Split	08.04.
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03.04.
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03.04.
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Tracon: Q4 Earnings Snapshot	05.03.
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	05.03.
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	05.03.
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024	28.02.
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20.12.
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20.12.
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	20.11.
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	20.11.
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment	20.11.
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10.11.
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	10.11.
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	10.11.
Top Premarket Gainers	10.11.
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Tracon: Q3 Earnings Snapshot	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TRACON Pharmaceuticals, Inc.

Aktien

A3EVGP

US89237H3084

TCON

Andere Sprachen

Filter